AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Imugene Limited has dosed the first patient in the intratumoral (IT) cohort 2 of its Phase 1 MAST study
- The study has been designed to measure the safety of novel cancer-killing virus CF33-hNIS (VAXINIA)
- The City of Hope-developed oncolytic virus has been shown to shrink ovarian, colon, lung, breast, and pancreatic cancer tumours in the preclinical laboratory and animal models
In the latest announcement, clinical-stage immuno-oncology company Imugene Limited (ASX:IMU) revealed that the first patient had been dosed within the intratumoral (IT) cohort 2 of the Phase 1 MAST (metastatic advanced solid tumours) study. The study has been designed to evaluate the safety of novel cancer-killing virus CF33-hNIS (VAXINIA). As part of the intravenous (IV) cohort 1 of the study, the first patient was dosed in September.
Following the update, IMU shares were spotted trading 4.54% higher at AU$0.172 per share at 12:08 PM AEDT.
Image Source: Company Announcement
To date, a multicenter Phase 1 trial, the VAXINIA Phase 1 MAST study, has delivered a low dose to patients having metastatic or advanced solid tumours with a minimum of two prior lines of the standard of care treatment. The City of Hope-developed oncolytic virus has been shown to shrink ovarian, colon, lung, pancreatic and breast cancer tumours in the preclinical laboratory and animal models.
The clinical trial is titled “A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33- hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination with Pembrolizumab in Adult Patients with Metastatic or Advanced Solid Tumours (MAST).”
Imugene expects the trial to be completed in around two years, sourcing capital from the company’s current budgets and resources.
Management Commentary
Image Source: ©2022 Kalkine Media®